Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical is supported by a dominant, well-entrenched surgical robotics ecosystem with more than 11,000 da Vinci systems installed worldwide, over 2,000 dV5 systems in the base, and a broad consumables-and-service model that creates recurring revenue. Its fundamentals remain attractive because 3Q showed stable U.S. procedure growth at 10%, strong dV5 placements at 274 units, and continued international momentum, while management highlighted long-term growth from benign general surgery, ASCs, cardiac, and other expanding indications. Although extended-use and China pricing actions create a temporary I&A per-procedure headwind, the company’s scale, best-in-class margins, high barriers to entry, and product-cycle upgrades should support durable revenue, EPS, and installed-base expansion.

Intuitive Surgical is facing a weaker fundamental setup as U.S. da Vinci procedure growth decelerated to 10% in Q3 from 12% in Q2 and 14% in Q1, while management narrowed FY26 procedure growth to 14.0%-15.0% without a clearer sign that U.S. volumes have troughed. China adds another layer of pressure, since it is only about 5%-6% of global procedures but remains challenging, with a policy-driven charge code change and planned I&A price reductions beginning in November 2026 expected to cut per-procedure revenue. At the same time, the company’s extended-use program and volume-based pricing could lower I&A revenue per procedure by ~3%-5%, limiting earnings leverage despite robust gross margins of 68.7%-69.3% guidance.